Emergent BioSolutions stock falls 11.14 percent on October 16, 2026

Published on 10/17/2026 at 19:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

H.C. Wainwright set USD 10.00 on September 9, 2026. Emergent BioSolutions stock stood at USD 6.38 on October 16, 2026, down 11.14 percent on NYSE.

NYSE decline reaches 11.14 percent

H.C. Wainwright set a USD 10.00 target on September 9, 2026.
The latest quote stood 54.62 percent below the 52-week high of USD 14.06.
Emergent BioSolutions stock last stood at USD 6.38 at 4:00 p.m. EDT on October 16, 2026, 11.14 percent below the October 15, 2026 NYSE close.
Third-quarter results are scheduled for November 2, 2026.

EBS, US29089Q1058, Illustration mit AI erstellt.

H.C. Wainwright set a USD 10.00 target for Emergent BioSolutions in a research note dated September 9, 2026, according to MarketBeat. Emergent BioSolutions (ISIN US29089Q1058) was last quoted at USD 6.38 on October 16, 2026 at 4:00 p.m. EDT on the NYSE, down 11.14 percent versus the October 15, 2026 NYSE close.

The yearly range remains wide

The latest quote sat 54.62 percent below the 52-week high of USD 14.06 and 46.33 percent above the 52-week low of USD 4.36. The gap highlights how sharply the stock's valuation has contracted within its yearly trading band.

Trading volume reached 2,237,072 shares on October 16, 2026, against an average volume of 1,180,075 shares. The session volume was 89.57 percent above that average, while the negative daily move placed the stock well below its recent high.

Valuation and reporting date

Emergent BioSolutions had a market capitalization of USD 327.1 million and a negative price-to-earnings ratio of 1.80 as of October 16, 2026. The company operates in specialty pharmaceuticals and develops vaccines, treatments and other products for public health threats.

The company is scheduled to report third-quarter 2026 financial results on November 2, 2026, according to Financial Times. The appointment gives investors a defined date for the next earnings update after the stock's latest decline.

The next market marker

The USD 10.00 analyst target is 56.74 percent above the October 16, 2026 NYSE quote. That comparison places the upcoming results release alongside a large gap between the latest market price and the target cited by H.C. Wainwright.

Emergent BioSolutions was last quoted at USD 6.38 on October 16, 2026 at 4:00 p.m. EDT on the NYSE, 11.14 percent below the October 15, 2026 NYSE close.